Detail BI 5700, A Selective Chemical Inhibitor Of I?B Kinase 2, Specifically Suppresses Epithelial-Mesenchymal Transition And Metastasis In Mouse Models Of Tumor Progression   Oleh:  Huber, Margit A. ; Maier, Harald J. ; Alacakaptan, Memetcan ; Wiedemann, Eva ; Braunger, Jürgen ; Boehmelt, Guido ; Madwed, Jeffrey B. ; Young, Erick R.R. ; Marshall, Daniel R. ; Pehamberger, Hubert ; Wirth, Thomas ; Kraut, Norbert ; Beug, Hartmut Jenis: Article from Article Dalam koleksi: Genes and Cancer vol. 1 no. 2 (May 2010), page 101-114. Topik: Epithelial-Mesenchymal Transition; Metastasis; IKK2; NF-?B; Chemical Inhibitor Fulltext: 101-14.pdf (1.0MB) Isi artikel Increasing evidence suggests that processes termed epithelial-mesenchymal transitions (EMTs) play a key role in therapeutic resistance, tumor recurrence, and metastatic progression. NF-?B signaling has been previously identified as an important pathway in the regulation of EMT in a mouse model of tumor progression. However, it remains unclear whether there is a broad requirement for this pathway to govern EMT and what the relative contribution of IKK family members acting as upstream NF-?B activators is toward promoting EMT and metastasis. To address this question, we have used a novel, small-molecule inhibitor of I?B kinase 2 (IKK2/IKKß), termed BI 5700. We investigated the role of IKK2 in a number of mouse models of EMT, including TGFß-induced EMT in the mammary epithelial cell line EpRas, CT26 colon carcinoma cells, and 4T1 mammary carcinoma cells. The latter model was also used to evaluate in vivo activities of BI 5700.We found that BI 5700 inhibits IKK2 with an IC50 of 9 nM and was highly selective as compared to other IKK family members (IKK1, IKKe, and TBK1) and other kinases. BI 5700 effectively blocks NF-?B activity in EpRas cells and prevents TGFß-induced EMT. In addition, BI 5700 reverts EMT in mesenchymal CT26 cells and prevents EMT in the 4T1 model. Oral application of BI 5700 significantly interferes with metastasis after mammary fat-pad injection of 4T1 cells, yielding fewer, smaller, and more differentiated metastases as compared to vehicle-treated control animals. We conclude that IKK2 is a key regulator of both the induction and maintenance of EMT in a panel of mouse tumor progression models and that the IKK2 inhibitor BI 5700 constitutes a promising candidate for the treatment of metastatic cancers. Opini Anda Klik untuk menuliskan opini Anda tentang koleksi ini! Kembali

Copyright © 2006, 2007 Unika Atma Jaya, all rights reserved